ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
7,921.30
0.76%
S&P ASX All Technology
3,078.20
0.32%
Brent Oil
79.745
0.00%
US Dollar vs AUD
1.52742
0.00%
Bitcoin
67,929.46
0.02%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. OSE Immunotherapeutics (OSE) Share Price

OSE Immunotherapeutics

OSE Immunotherapeutics (OSE)

EU
7.61
0.70
(10.13%)
Closed 27 July 1:30AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
7.61
Bid
7.45
Offer
7.65
Volume
464,450
6.84 Day's Range 7.67
2.705 52 Week Range 8.63
Market Cap
165.653M
Previous Close
6.91
Open
6.90
Last Trade
500
@
7.61
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
194,568
Shares Outstanding
21,767,777
Dividend Yield
-
PE Ratio
-7.20
Earnings Per Share (EPS)
-1.06
Revenue
2.23M
Net Profit
-23M

About OSE Immunotherapeutics

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Website
www.ose-immuno.com
Headquarters
Nantes, Loire-atlantique, Fra
Founded
1970
OSE Immunotherapeutics is listed in the Coml Physical, Biologcl Resh sector of the Euronext with ticker OSE. The last closing price for OSE Immunotherapeutics was 6.91 €. Over the last year, OSE Immunotherapeutics shares have traded in a share price range of 2.705 € to 8.63 €.

OSE Immunotherapeutics currently has 21,767,777 shares in issue. The market capitalisation of OSE Immunotherapeutics is 150.42 € million. OSE Immunotherapeutics has a price to earnings ratio (PE ratio) of -7.20.

OSE Latest News

More News

OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis

OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis Lusvertikimab demonstrates significant efficacy during the...

24 July 2024
GlobeNewswire Inc.

OSE Immunotherapeutics annonce des résultats positifs d'efficacité de Lusvertikimab dans l'essai clinique de phase 2 pour le traitement de la rectocolite hémorragique

OSE Immunotherapeutics annonce des résultats positifs d'efficacité de Lusvertikimab dans l'essai clinique de phase 2 pour le traitement de la rectocolite hémorragique OSE...

24 July 2024
UK Regulatory

OSE Immunotherapeutics et Boehringer Ingelheim poursuivent l’avancée du développement clinique du traitement first-in-class SIRPα BI 770371 en immunologie du cancer

OSE Immunotherapeutics et Boehringer Ingelheim poursuivent l’avancée du développement clinique du traitement first-in-class SIRPα BI 770371 en immunologie du cancer OSE Immunotherapeutics et...

04 July 2024
GlobeNewswire Inc.

Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371

Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371   Ingelheim, Germany and Nantes, France, 3 July 2024 –...

04 July 2024
GlobeNewswire Inc.

Informations relatives au nombre total de droits de vote et d’actions composant le capital

Informations relatives au nombre total de droits de vote et d’actions composant le capital Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes...

03 July 2024
GlobeNewswire Inc.

OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’ 

OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’  OSE Immunotherapeutics...

01 July 2024
GlobeNewswire Inc.

OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-T

OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-T OSE Immunotherapeutics annonce un accord commercial et de partage...

24 June 2024
GlobeNewswire Inc.

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies NANTES, France, June 24, 2024 – 7:30am CET - OSE Immunotherapeutics SA (ISIN:...

24 June 2024
GlobeNewswire Inc.

OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San Francisco (18 – 21 juin)

OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San...

20 June 2024
GlobeNewswire Inc.

OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)

OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 –...

20 June 2024
GlobeNewswire Inc.
Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
10.8212.07658321066.797.676.421410676.62976081DE
41.7529.86348122875.867.675.371521946.52329979DE
121.3721.95512820516.248.635.371945686.98586955DE
263.7697.66233766233.858.633.1151683856.09792878DE
524.19122.5146198833.428.632.7051859695.38239733DE
156-1.29-14.49438202258.913.682.705925166.20332957DE
2603.92106.2330623313.6915.82.705854127.19889442DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VPRVolt Group Ltd
AUD 0.002
(100.00%)
12.5k
KNBOKoonenberry gold Ltd
AUD 0.004
(100.00%)
260.57k
WOAOWide Open Agriculture Ltd
AUD 0.003
(50.00%)
1M
MCTMetalicity Ltd
AUD 0.003
(50.00%)
1.33M
INDIndustrial Minerals Limited
AUD 0.255
(41.67%)
151.45k
ESROBEstrella Resources Limited
AUD 0.001
(-50.00%)
2M
FG1OFlynn Gold Limited
AUD 0.004
(-42.86%)
2.02M
OVTOvanti Ltd
AUD 0.003
(-40.00%)
6.24M
CPOOCulpeo Minerals Ltd
AUD 0.008
(-33.33%)
400k
IMIInfinity Mining Ltd
AUD 0.01
(-28.57%)
232.1k
BGLBellevue Gold Limited
AUD 1.45
(-20.98%)
80.17M
E79E79 Gold Mines Ltd
AUD 0.041
(20.59%)
56.75M
AGYArgosy Minerals Inc
AUD 0.049
(40.00%)
53.8M
JRVJervois Global Ltd
AUD 0.016
(6.67%)
42.87M
REDRed 5 Limited
AUD 0.375
(-5.06%)
36.66M

Discussion

View Full Feed
BOREALIS BOREALIS 3 minutes ago
HARRIS

https://pbs.twimg.com/media/GTOHY5oXsAATHUX.jpg

https://pbs.twimg.com/media/GTD8m4dXcAAYr7-.jpg

https://pbs.twimg.com/media/GTHE3YObcAEEm9Q.jpg
BoscoLives21 BoscoLives21 3 minutes ago
Remember Shakespeare’s famous quote — “Methinks (s)he doth protest too much!”
Commenting objectively on the doings of our fine company is a far cry from promotion — it’s simply level-headed observation.
14 distinct brews and counting!!
WAY TO GO €KEGS!!
KEGS
cadillacdave cadillacdave 4 minutes ago
Hopefully, he is doing a better job behind the scenes in making a deal come to fruition.
WDDD
cojoboy cojoboy 6 minutes ago
I'm sorry..did I miss the news where PHIL actually "purchased" anything..???
PHIL
Whalatane Whalatane 6 minutes ago
Opinion by Dew who I think is ex Harvard Med
Member Level
Re: Whalatane post# 252682
Thursday, July 25, 2024 10:04:04 PM
Post# of 252696
ARDX/UNCY—As noted earlier, the reversal of the "Chevron" doctrine by the US Supreme Court should give the plaintiffs in this
ARDX UNCY
mick mick 7 minutes ago
WHAT IS THE NEXT TOUR ELI ????? ANYONE
Nemesis18 Nemesis18 7 minutes ago
I think that it is safe to assume that review process started with the best intentions, but as more matters were discovered, the proposed accelerated timeline simply got tossed out of the regulatory window.?
NWBO
FALCON1 FALCON1 8 minutes ago
little gem ELTP alongside the big boys Pfizer, Morgan Stanley Donaher...
"Elite Pharmaceuticals' shares have outperformed the Zacks Medical – Drugs industry over the past two years (+302.3% vs. -16.8%). The Zacks analyst believes that the successful commercial launch of the company's Elit
ELTP
The_Gman The_Gman 8 minutes ago
I still have a can of Platinum and a can of Cherry Vanilla. Stamp says best by 2022. Ah, the good ole days!
KGKG
sylvia07 sylvia07 9 minutes ago
Janet, this is from adim!
Icon for IH Admin [Shelly]
IH Admin [Shelly]

Friday, July 26, 2024 5:31:14 PM

I show that you stickied a video. Not sure what the other Member is talking about.
GRST
jhdf51 jhdf51 9 minutes ago
Escrow is no longer nor should have been the moment at hand...COOP is. If escrow comes after years and years fine, but I making good money on the stock, and have make alot since inception and when it fell back a couple years ago...

This is gonna be one for the record books in the futu
COOP
mzasif mzasif 10 minutes ago
Very nice close today!!! Oh wow! so many videos on YouTube mean they are so well-known around social media...that is a good thing and that is all i care about.

Next week will be going above .03 >> HUGE REVERSAL expected!! >> Make sure you hold your ticket for the next ride up, otherwi
BNCM
JACKPOT JACKPOT 11 minutes ago
It doesn't end...Illinois trucking company, brokerage file for bankruptcy liquidation

Blue Thunder Trucking, founded in 1988, had 75 drivers before ceasing operations and filing for Chapter 7

TLSS
WillForeall WillForeall 11 minutes ago
Who cares... you see this ?

https://www.otcmarkets.com/otcapi/company/financial-report/407852/content
HIRU
236T568 236T568 11 minutes ago
Geesh, listen to this old man. He is not well

https://x.com/gtconway3d/status/1816890419789041731?s=19
FeMike FeMike 11 minutes ago
Cvm offering. When's nwbo offering?

Probably not til we at least have a 50% gainer like CVM did yesterday.
CVM
Scott 75 Scott 75 11 minutes ago
I hope so. I've got an order for 190
TSLA
ZJ Pick ZJ Pick 11 minutes ago
You know why the low volume? BECAUSE PEOPLE ARENT SELLING. The impatient and idiots are out
SMCE
sylvia07 sylvia07 12 minutes ago
Janet, it was just a glitch because Bubae sticky was not highlighted in yellow either but is now'
GRST
OldAIMGuy OldAIMGuy 12 minutes ago
I vote for Rocky & Bullwinkle!

OAG
trader59 trader59 12 minutes ago
Down, boy... he's been asking pretty good questions of the fabricators for some time.
Iggy_Bot Iggy_Bot 14 minutes ago
20 years ago the pool was packed clams, kegs, pig on the spit and 1/2 of the town packed in my yard.. of course
country music blasting........ https://www.youtube.com/watch?v=TQML3jIC_9I
tat4tat tat4tat 14 minutes ago
Oh my goosh. The iHUB buyout bit, and merger bit as well. Something very suspicious about a stock that spikes from 10 cents to 48 cents on no news. This dead weight couldnt get back to ten cents on acquistion closing. Buck by some distant date in the reimagined future. Officers wayboverpaid. Clowns
CEOS
Testpilot Testpilot 14 minutes ago
Here's a more detailed outline of the SEC filings necessary for closing a share exchange agreement and their typical filing timelines:

1. *Form 8-K (Signing)*: File within 4 business days of signing the share exchange agreement.
- Disclose the signing of the agreement, its
CRTG

Your Recent History

EU
OSE
OSE Immunotherapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved